6/25/2023 0 Comments Amcp dossier![]() However, MCO respondents indicated that only 40% of all drugs they reviewed included dossiers from the manufacturers. Nearly all (87.5%) of the MCO personnel contacted reviewed dossiers within their organization. Representatives from 20 MCOs and 7 pharmaceutical manufacturers completed the interview 21 MCO representatives refused to participate, citing company policy. The interview was designed to assess the following key areas: economic models, organizational burden, confidentiality, overall value, and future expectations. Respondents from both pharmaceutical manufacturers and MCOs nationwide were familiar with the AMCP dossier preparation and review process, allowing us to compare perspectives from each group. Telephone interviews were conducted by 2 researchers between September 2004 and October 2005. Pharmaceutical manufacturer respondents were identified from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation's Health Outcomes Committee. ![]() The purpose of this research was to gain the perspectives of a sample of managed care organizations (MCOs) and pharmaceutical manufacturers regarding the AMCP Format submission and evaluation process, as well as their comments on possible future direction for these guidelines as an important part of the formulary decision-making process.Ī random sample of large (>1 million lives) and small (<1 million lives) MCOs was generated using telephone numbers from the National Directory of Managed Care Organizations' database. The Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions was intended as a tool to assist health care providers in evaluating and selecting drug products.
0 Comments
Leave a Reply. |